Search results
Results from the WOW.Com Content Network
As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. [citation needed] It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. [1]
Currently, the ABVD chemotherapy regimen is the standard treatment of Hodgkin's disease in the US. The abbreviation stands for the four drugs Adriamycin, bleomycin, vinblastine, and dacarbazine. Developed in Italy in the 1970s, the ABVD treatment typically takes between six and eight months, although longer treatments may be required.
The treatment is usually administered in four week cycles, often for six cycles. MSD and VCR are administered intravenously, while procarbazine and prednisone are pills taken orally. A newer Hodgkin lymphoma treatment is ABVD. C-MOPP involves switching the nitrogen mustard from mechlorethamine to cyclophosphamide.
Advanced Hodgkin disease requires systemic chemotherapy, sometimes combined with radiotherapy. [60] Chemotherapy used includes the ABVD regimen, which is commonly used in the United States. Other regimens used in the management of Hodgkin lymphoma include BEACOPP and Stanford V. Considerable controversy exists regarding the use of ABVD or BEACOPP.
A chemotherapy regimen is a regimen for chemotherapy, ... ABVD: doxorubicin (Adriamycin), ... relapsed non-Hodgkin's lymphoma and Hodgkin's lymphoma
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...
Vinblastine is a component of a number of chemotherapy regimens, including ABVD for Hodgkin lymphoma, and along with methotrexate in the treatment of aggressive fibromatosis (desmoid tumor). [5] [6] It is also used to treat histiocytosis according to the established protocols of the Histiocytosis Association.
BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group [1] used for patients in Stages > II or early (IA or IB) with unfavorable risk factors. [2] Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21. [3]